SIREN : 448974253
OXY PHARM is a French company founded 22 years ago, specialized in the sector Fabrication de matériel médico-chirurgical et dentaire. Based in CHAMPIGNY-SUR-MARNE (94500), this company of category PME shows in 2020 a revenue of 35.7 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2023 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | N/C | 35 748 408 € | 7 927 999 € | 6 848 628 € | 5 705 139 € | 4 984 572 € |
| Net income | 708 393 € | 13 955 688 € | 1 833 010 € | 1 721 927 € | 1 603 234 € | 394 125 € |
| EBITDA | N/C | 20 723 282 € | 2 658 437 € | 2 629 911 € | 2 656 398 € | 1 485 176 € |
| Net margin | N/C | 39.0% | 23.1% | 25.1% | 28.1% | 7.9% |
In 2023, OXY PHARM generates positive net income of 708 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2023: 394 k€ -> 708 k€.
708 393 €
The debt ratio (= Financial debt / Equity x 100) stands at 12%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
12.495%
79.713%
50.9%
In 2023, the debt ratio of OXY PHARM (12.49) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2023, the financial autonomy of OXY PHARM (79.7%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2020, the repayment capacity of OXY PHARM (0.29) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 331.86. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
331.862
In 2023, the liquidity ratio of OXY PHARM (331.86) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
In 2020, the interest coverage of OXY PHARM (0.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Based on 57 transactions of similar company sales
(all years),
the value of OXY PHARM is estimated at
2 157 538 €
(range 501 384€ - 4 254 569€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 57 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare OXY PHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de matériel médico-chirurgical et dentaire
The revenue of OXY PHARM in 2020 is 35.7 M€.
Yes, OXY PHARM generated a net profit of 708 k€ in 2023.
The headquarters of OXY PHARM is located in CHAMPIGNY-SUR-MARNE (94500), in the department Val-de-Marne.
The tax return of OXY PHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
OXY PHARM operates in the sector Fabrication de matériel médico-chirurgical et dentaire (NAF code 32.50A). See the 'Sector positioning' section above to compare the company with its competitors.